This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit January 16, 2015
Home    About AST    Education    Meetings & Events    Public Policy    Contact Us  



AST Transplant Diagnostics COP provides voice for transplantation for the FDA
VideoBrief Dr. Parmjeet Randhawa, chair of the Transplant Diagnostics COP, spoke on AST's behalf at the FDA’s two-day meeting on LDTs on January 9 regarding the direct impact and consequences of newly proposed FDA policy for Laboratory Developed Tests (LDTs). This invitation from the FDA to speak is significant, as not all who wished to present were being given this opportunity. FDA officials, select Congressional staff from Capitol Hill, and the entire clinical laboratory community attended this meeting, as the LDT issue is quickly being hailed as one the more visible clinical lab issues in a long time.

AST’s Transplant Diagnostics Community of Practice (Tx Dx COP) prepared a one-page document on the impact of the FDA guidance framework on transplantation. This document, approved by the AST Board of Directors, can be read here.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

FQAPI webinar, hosted by CMS, AST, and ASTS
Please join us as we review the Focused Quality Assessment and Performance Improvement Survey (FQAPI) pilot program and plans for 2015. This free webinar will highlight the link between QAPI and the mitigating factors process.

This free webinar will be held on Friday, Jan. 30, 2015 at 12 p.m. EST (noon), and is open to all transplant professionals. We welcome all members of your transplant team to register today:

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Discounted Early Registration & Hotel Rates for a Limited Time Only
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies

Feb. 5-7, 2015
Sheraton Wild Horse Pass – Chandler, Arizona

CEOT 2015 is fast approaching, and for a limited time you can save on registration and housing with special discounted promotions. Attend CEOT with a colleague and take advantage of the “Buy One, Get One Half Off” registration, now extended through February 7. Going solo? Early registration discounted rates are in effect from now until Jan. 23. Join nearly 300 of your colleagues at this high-energy, interactive meeting to explore how we, as a community involved in transplantation, will move the field forward.

This year’s CEOT will explore some of the following critical challenges:
  • How can you participate in the future of new drug development?
  • How do we pioneer the repositioning of existing and new drugs?
  • How can AST champion the necessary change that affords your patients better outcomes?
Click here to register for CEOT at a discount.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE


Prospective iterative trial of proteasome inhibitor-based desensitization
American Journal of Transplantation
A prospective iterative trial of proteasome inhibitor (PI)-based therapy for reducing HLA antibody (Ab) levels was conducted in five phases differing in bortezomib dosing density and plasmapheresis timing. Phases included 1 or 2 bortezomib cycles (1.3 mg/m2 × 6–8 doses), one rituximab dose and plasmapheresis. HLA Abs were measured by solid phase and flow cytometry (FCM) assays. Immunodominant Ab (iAb) was defined as highest HLA Ab level.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

5-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: The randomized ZEUS study
American Journal of Transplantation
ZEUS study was an open-label, 12-month, multicenter study in which 300 de novo kidney transplant recipients were randomized to continue receiving cyclosporine (CsA) or convert to everolimus at 4.5 months posttransplant. Five-year follow-up data were available for 245/269 patients (91.1 percent) who completed the core 12-month study (123 everolimus, 109 CsA). At 5 years, adjusted estimated GFR was 66.2 mL/min/1.73 m2 with everolimus versus 60.9 mL/min/1.73 m2 with CsA; the mean difference was 5.3 mL/min/1.73 m2 in favor of everolimus .
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.

Viral metagenomics reveal blooms of anelloviruses in the respiratory tract of lung transplant recipients
American Journal of Transplantation
Few studies have examined the lung virome in health and disease. Outcomes of lung transplantation are known to be influenced by several recognized respiratory viruses, but global understanding of the virome of the transplanted lung is incomplete. To define the DNA virome within the respiratory tract following lung transplantation we carried out metagenomic analysis of allograft bronchoalveolar lavage (BAL), and compared with healthy and HIV+ subjects.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Novel biomarkers and functional assays to monitor cell-therapy-induced tolerance in organ transplantation
Current Opinion in Organ Transplantation
Cell-based immunotherapy offers a novel approach to minimize the need for immunosuppressive drugs and to promote a state of immunological tolerance to a transplanted organ. We review the most promising biomarkers and functional assays able to identify patients tolerant to their graft. Such a signature of tolerance is essential in the assessment of the efficacy with which trials of cellular therapies promote immunoregulation and minimize graft rejection.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Liver transplantation for neonatal hemochromatosis: Analysis of the UNOS database
Pediatric Transplantation
NH is the most common identifiable cause of ALF in the neonate. LT is the definitive treatment for neonates with NH who have failed medical therapy. Our aim was to determine the outcomes of LT in infants with NH. Patients (less than one yr of age) with NH who were listed for LT and patients who underwent LT between 1994 and 2013 were identified from the UNOS database for analysis. Risk factors for death and graft loss were analyzed by multivariate logistic regression.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Influence of donor and recipient age in lung transplantation
The Journal of Heart and Lung Transplantation
A retrospective cohort study was performed of lung transplant recipients from 1987 to 2013 through a query of the United Network for Organ Sharing (UNOS) thoracic database. Age thresholds used were recipients (R) aged 60 years (R60 group) and 65 years (R65 group) and donors aged 50 years; each sub-group was analyzed, totaling 8 groups.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Missed last week's issue? See which articles your colleagues read most.

    Sirolimus use and cancer incidence among US kidney transplant recipients (American Journal of Transplantation)
Through a glass darkly: Seeking clarity in preventing late kidney transplant failure (Journal of the American Society of Nephrology)
Usability testing of the Internet program: 'Teens Taking Charge: Managing My Transplant Online' (Pediatric Transplantation)
Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients (Pediatric Transplantation)

Don't be left behind. Click here to see what else you missed.

AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Julie Bernhard, Executive Editor, 469.420.2647  
Contribute news

This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Jan. 9, 2015
Jan. 2, 2015
Dec. 26, 2014
Dec. 19, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063